Reports

Ideas That Generate Results

Figure 4-1: %age of CF individuals over the age of 18
Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016
Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients
Figure 5-1: Global – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 6-1: Global - Sales of Orkambi (Million US$), 2015 & 2016
Figure 6-2: Global - Sales of Kalydeco (Million US$), 2012-2016
Figure 6-3: Global - Sales of Cayston (Million US$), 2014-2016
Figure 6-4: Global - Sales of Pulmozyme (Million US$), 2012-2016
Figure 6-5: Global - Sales of TOBI (Million US$), 2014-2016
Figure 6-6: Global - Sales of Creon (Million US$), 2014-2016
Figure 6-7: Global - Sales of Zenpep (Million US$), 2014-2016
Figure 6-8: Global - Sales of Ventolin (Million US$), 2014-2016
Figure 6-9: Global - Sales of Bronchitol (Million US$), 2014-2016
Figure 7-1: Global – Cystic Fibrosis Therapeutics Market Breakup by Pharmacological Class (%), 2016
Figure 7-2: Global - CFTR Modulator Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-3: Global - Mucolytic Agents Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-4: Global - Pancreatic Enzyme Replacement Products Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-5: Global – Antibiotics Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-6: Global – Other Therapies Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-1: Global – Cystic Fibrosis Therapeutics Market by Drug Molecule Type (%), 2016
Figure 8-2: Global - Small Molecule Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-3: Global - Biologic Drugs Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-1: Global - Cystic Fibrosis Therapeutics Market Breakup by CF Mutation Type (%), 2016
Figure 9-2: Global – Class I Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-3: Prevalence of the F508del Mutation in Patients with Cystic Fibrosis (% of Patients with at Least 1 Allele)
Figure 9-4: Global – Class II Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-5: Global – Class III Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 10-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Geography (%), 2016
Figure 10-2: North America - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-3: Europe - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-4: Asia-Pacific – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 12-1: Global - Cystic Fibrosis Clinical Trials by Phase till June, 2017
Figure 12-2: Global - Cystic Fibrosis Clinical Trials by Key Players till June, 2017
Figure 12-3: Global – Cystic Fibrosis Clinical Trials by Countries till June, 2017
Figure 12-4: Global – Cystic Fibrosis Clinical Trials by Route of Administration till June, 2017
Figure 14-1: Global - Share of Major Players in Cystic Fibrosis Therapeutics Market (%), 2016
Figure 15-1: F. Hoffman La Roche Ltd. - Breakup of Revenue by Business Segments (%), 2016
Figure 15-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Geography (%), 2016
Figure 15-4: Novartis - Sales by Business Segments (%), 2016
Figure 15-5: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
Figure 15-6: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 15-7: Novartis - Sales by Geography (%), 2016
Figure 15-8: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Product (%), 2016
Figure 15-9: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Geography (%), 2016
Figure 15-10: Abbott Laboratories – Net Sales Breakup by Business Segments (%), 2016
Figure 15-11: Abbott Laboratories – Net Sales Breakup by Geography (%), 2016
Figure 15-12: Gilead Sciences, Inc. - Breakup of Revenue by Geographic Segments (%), 2016
Figure 15-13: Johnson & Johnson - Sales by Business Segments (%), 2016
Figure 15-14: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
Figure 15-15: Johnson & Johnson - Sales by Geography (%), 2016
Figure 15-16: Allergan plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-17: Allergan plc - Breakup of Revenue by Geography (%), 2016
Figure 15-18: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-19: GlaxoSmithKline plc - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-20: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016
Figure 15-21: Mylan N.V. - Breakup of Revenue by Geographic Region (%), 2016
Figure 15-22: Pharmaxis Ltd - Breakup of Revenue by Business Segment (%), 2016
 
List of Tables:

Table 4 -1: Global - Key Cystic Fibrosis Drugs and Patent Expiry Status
Table 12-1: Global – Cystic Fibrosis Products Pipeline Analysis
Table 14-1: Global - Major Cystic Fibrosis Drugs
Table 15-1: F. Hoffman La Roche Ltd. - Key Financials (Billion US$), 2014-2016
Table 15-2: Genentech, Inc. - Commercialized Cystic Fibrosis Product
Table 15-3: Genentech, Inc. - Cystic Fibrosis Drugs in Pipeline
Table 15-4: Novartis – Key Financials (Billion US$), 2014-2016
Table 15-5: Novartis - Commercialized Cystic Fibrosis Product
Table 15-6: Novartis - Cystic Fibrosis Drugs in Pipeline
Table 15-7: Vertex Pharmaceuticals Incorporated – Key Financials (Million US$), 2014-2016
Table 15-8: Vertex Pharmaceuticals Incorporated - Commercialized Cystic Fibrosis Product
Table 15-9: Vertex Pharmaceuticals Incorporated - Cystic Fibrosis Drugs in Pipeline
Table 15-10: Abbott Laboratories – Key Financials (Million US$), 2014-2016
Table 15-11: Abbott Laboratories - Commercialized Cystic Fibrosis Product
Table 15-12: Gilead Sciences, Inc. - Key Financials (Billion US$), 2014-2016
Table 15-13: Gilead Sciences, Inc. - Commercialized Cystic Fibrosis Product
Table 15-14: Gilead Sciences, Inc. – Cystic Fibrosis Drugs in Pipeline
Table 15-15: Johnson & Johnson – Key Financials (Billion US$), 2014-2016
Table 15-16: Johnson & Johnson - Commercialized Cystic Fibrosis Product
Table 15-17: Allergan plc - Key Financials (Million US$), 2014-2016
Table 15-18: Allergan plc - Commercialized Cystic Fibrosis Product
Table 15-19: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016
Table 15-20: GlaxoSmithKline plc - Commercialized Cystic Fibrosis Product
Table 15-21: GlaxoSmithKline plc – Cystic Fibrosis Drugs in Pipeline
Table 15-22: Mylan N.V. - Key Financials (Million US$), 2014-2016
Table 15-23: Mylan N.V. - Commercialized Cystic Fibrosis Product
Table 15-24: Pharmaxis Ltd - Key Financials (Million US$), 2014-2016
Table 15-25: Pharmaxis Ltd - Commercialized Cystic Fibrosis Product
Table 15-26: Pharmaxis Ltd – Cystic Fibrosis Drugs in Pipeline